ClinicalTrials.gg
Not yet recruitingNCT07907822STRIKEUpdated Oct 30, 2026

A Study to Evaluate the Effectiveness and Safety of S-amlodipine-based Monotherapy and Combination Therapy

An observational study in Hypertension (HTN), Hypertension and Essential (Primary) Hypertension, sponsored by Ahn-Gook Pharmaceuticals Co.,Ltd. Not yet recruiting. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2026-10-30.

Sponsored by Ahn-Gook Pharmaceuticals Co.,Ltd · Observational

Updated Oct 30, 2026Newly registeredGo to Updates ↓
Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
4,528
Ages
19 Years and older
Sex
All
01

Study summary

This study aims to evaluate the effectiveness, safety, and clinical utility as a treatment strategy of the s-amlodipine-based monotherapy, dual combination, and triple combination in patients with hypertension across various stages of blood pressure control in routine clinical practice.

02

Conditions studied

  • Hypertension (HTN)
  • Hypertension
  • Essential (Primary) Hypertension
03

In context

Hypertension

6,114 studies on the registry are indexed under Hypertension; 912 are open to participants now.

This study's planned enrollment of 4,528 is above the median of 350 across 1,163 observational studies indexed under Hypertension.

Browse Hypertension studies →

Lead sponsor

Ahn-Gook Pharmaceuticals Co.,Ltd is the lead sponsor of 24 studies on the registry; 5 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
19 Years and older
Sexes eligible
All
Sampling method
Non-probability sample

Study population

Essential hypertensive patients in need of a monoterapy or combination treatment with S-amlodipinne based antihypertensive agents

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients who voluntarily consent on the form and understand the study's purpose, methods, and so on
  • Males and females over the age of 19
  • Patients who have been diagnosed with essential hypertension and plan to be treated with S- amlodipine or S-amlodipine/Valsartan or S-amlodipine/Valsartan/Indapamide

Exclusion criteria

Exclusion Criteria:

The patients who meet any of the following exclusion criteria cannot participate in this study.

  • The patients who are for the administration of the study drug according to the approved label
  • The patients who are pregnant, possibly pregnant, or lactating women = The patients who are judged by the investigator to be inappropriate for participation in this study
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
4,528 participants (estimated)
Patient registry
No

Groups and cohorts

  • Monotherapy cohort
  • Combination therapy cohort
06

What researchers measure

Primary outcomes

  1. The blood pressure control rate

    The blood pressure control rate (\< 140/90 mmHg)(Systolic and Diastolic) at Week 12

    Time frame: Week 12

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

1 registry update since Sep 25, 2026
Registered
First appeared on the registry. No changes since
Oct 30, 2026
Show all 1 update
  1. Oct 30, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07907822
Responsible party
Sponsor
First posted
Oct 30, 2026
Start date
Nov 1, 2026 (estimated)
Primary completion
Feb 28, 2029 (estimated)
Completion
Oct 31, 2029 (estimated)
Last update
Oct 30, 2026

Study contacts

Hyunji Kim
Contact
hyunji.kim@ahn-gook.com
82-2-3289-4215
Hae-Young Lee
principal investigator · Seoul National University Hospital

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion